Send to

Choose Destination
Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27.

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Author information

Dana-Farber Cancer Institute, Boston, MA.
Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, NE.
Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY.
Seidman Cancer Center, University Hospitals, Cleveland, OH.
Charles A. Sammons Cancer Center, Dallas, TX.
Colorado Blood Cancer Institute, Denver, CO.
Mayo Clinic, Rochester, MN.
St. Francis Hospital, Greenville, SC.
The Jewish Hospital-Mercy Health, Cincinnati, OH.
Pacific Hematology Oncology Associates, San Francisco, CA.
The Oncology Institute of Hope & Innovation, Whittier, CA.
Division of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, AL.
Seattle Genetics, Inc, Bothell, WA; and.
Stanford Cancer Institute, Stanford, CA.


Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline chemotherapy. Achievement of complete remission (CR) with pre-ASCT salvage chemotherapy predicts favorable outcomes post-ASCT. This phase 1/2 study evaluated the combination of brentuximab vedotin (BV) plus bendamustine as a first salvage regimen in relapsed/refractory HL. A total of 55 patients (28 primary refractory and 27 relapsed) were enrolled. Patients received BV (1.8 mg/kg) on day 1 and bendamustine (90 mg/m2) on days 1 and 2 of a 21-day cycle for up to 6 cycles. Patients could undergo ASCT any time after cycle 2. Following ASCT or completion of combination therapy if not proceeding to ASCT, patients could receive BV monotherapy for up to 16 cycles of total therapy. After a median of 2 cycles of combination therapy (range, 1-6), the objective response rate among 53 efficacy-evaluable patients was 92.5%, with 39 patients (73.6%) achieving CR. Forty patients underwent ASCT. Thirty-one patients (25 of whom underwent ASCT) received BV monotherapy (median, 10 cycles; range, 1-14). After a median of 20.9 months of follow-up, the estimated 2-year progression-free survival was 69.8% and 62.6% for patients who received ASCT and all patients, respectively. Thirty-one patients (56.4%) experienced infusion-related reactions (IRRs), with a majority occurring during cycle 2 of combination therapy. A protocol amendment requiring premedication reduced IRR severity. BV plus bendamustine as first salvage therapy in relapsed/refractory HL is highly active with a manageable toxicity profile. This trial was registered at as #NCT01874054.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center